Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

Overview of attention for article published in Angiogenesis, February 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#17 of 595)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 1 news outlet
policy: 2 policy sources
twitter: 3 X users

patent: 71 patents
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 849 Dimensions

Readers on

mendeley: 531 Mendeley

Summary News Policy documents X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 8 policy documents that reference this research output.

Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions

Cited by Canadian Agency for Drugs and Technologies in Health on 07 Feb 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Aflibercept for treating choroidal neovascularisation: Committee papers

Cited by National Institute for Health and Care Excellence on 15 Sep 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Aflibercept

Cited by Canadian Agency for Drugs and Technologies in Health on 26 Oct 2016

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion: Committee papers

Cited by National Institute for Health and Care Excellence on 08 Jun 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions

Cited by Canadian Agency for Drugs and Technologies in Health on 09 Jul 2015

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion: Macular oedema (central retinal vein occlusion) - aflibercept solution for injection: evaluation report

Cited by National Institute for Health and Care Excellence on 08 Jan 2014

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Aflibercept solution for injection for treating wet age‑related macular degeneration: Macular degeneration (wet age-related) - aflibercept (1st line): evaluation report

Cited by National Institute for Health and Care Excellence on 11 Jul 2013

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy: Colorectal cancer (metastatic) - aflibercept: evaluation report

Cited by National Institute for Health and Care Excellence on 21 Jun 2013

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.